Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.
OBJECTIVE
The purpose of this study was to examine the influence of narrowband ultraviolet (NB-UVB) therapy on the serum concentration of soluble tumor necrosis factor receptor type 1 (sTNF-R1) in psoriasis patients.


METHODS
Twenty-seven patients received NB-UVB therapy three to five times a week for 4 weeks. The assessment of skin lesions using psoriasis area and severity index (PASI) and serum concentration of sTNF-R1 was performed at the baseline, at 2, 4 and 4 weeks after treatment cessation. The sera of healthy subject were used as controls.


RESULTS
The baseline PASI was 13.56 +/- 5.71, sTNF-R1 concentration was 1.89 +/- 0.43 ng/ml in patients and 1.48 +/- 0.30 ng/ml in controls (P < 0.05). The baseline PASI correlated to sTNF-R1 (r = 0.52, P < 0.05). The decline in concentrations of sTNF-R1 paralleled the decline of PASI achieved during therapy but still exceeded control values.


CONCLUSIONS
The results of the study confirm the role of sTNF-R1 as a marker of psoriasis severity and efficacy of treatment. They also suggest that NB-UVB influences the serum level of sTNF-R1.
Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland. agabser@amb.edu.pl
Agnieszka Beata
AB
Serwin
Marianna
M
Sokolowska
Bozena
B
Chodynicka
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000532:radiotherapy*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy
D047888:Receptors, Tumor Necrosis Factor, Type I